Effects Of Baibankeli Ⅰ To IL-22and Anti-tyrosinase Antibodies Of Patients With Vitiligo

Objective: This study tests levels of anti-tyrosinase antibodies and interleukin22(IL-22) expression of vitiligo patients and healthy controls. And analyze the relative levels of anti-tyrosinase antibodies and IL-22of vitiligo patients before and after the treatment of Baibankeli I, also compare with the control group of patients who is not using Baibankeli I. Thus verifying immunological basis of Baibankeli I in the treatment of vitiligo, and basing for the development and promotion of new drugs.Methods:The levels of IL-22mRNA in Peripheral blood mononuclear cells(PBMC) from patients with Baibankeli I and the control group before and after treatment and healthy controls was detected by Real-time quantitative (RT-PCR). The levels of anti-tyrosinase antibodies and IL-22in serum from patients with Baibankeli I and the control group before and after treatment and healthy controls was detected by enzyme-linked immunosorbent assay (ELISA). Using statistical methods for the analyze its changes.Results1. Comparing with healthy controls, the levels of IL-22mRNA in PBMC and IL-22protein/anti-tyrosinase antibody in serum of vitiligo patients were significantly higher, the difference was statistically significant (P＜0.05).2. After3months treatment, the level of IL-22mRNA/IL-22protein/anti-tyrosinase antibody levels of vitiligo patients with Baibankeli I lower than before treatment, the difference was statistically significant (P＜0.05); so as the control group. But, after the3months treatment, all indexes of vitiligo patients with Baibankeli I were more closer to normal levels than the control group, the difference between the two groups was statistically significant (P＜0.05).Conclusions1. Comparing with healthy controls, the levels of IL-22mRNA in PBMC and IL-22protein/anti-tyrosinase antibody in serum of vitiligo patients were significantly higher. We suggest that IL-22and anti-tyrosinase antibodies play a role in the pathogenesis of vitiligo.2. After3months treatment, the level of IL-22mRNA/IL-22protein/anti-tyrosinase antibody levels of vitiligo patients with Baibankeli Ⅰ lower than before treatment; so as the control group. But, after the3months treatment, the difference of all indexes of vitiligo patients with Baibankeli Ⅰ were higher than the control group and closer to normal levels. We suggest that Baibankeli Ⅰ may regulate the immune of vitiligo patients via adjusting the level IL-22and anti-tyrosinase antibody.